Palvella shares fell sharply after the FDA declined to grant Breakthrough Therapy Designation for QTORIN in cVMs, but the decision does not change ...
Source LinkPalvella shares fell sharply after the FDA declined to grant Breakthrough Therapy Designation for QTORIN in cVMs, but the decision does not change ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.